CN111067973A - Callicarpa nudiflora gel for treating gynecological inflammation - Google Patents
Callicarpa nudiflora gel for treating gynecological inflammation Download PDFInfo
- Publication number
- CN111067973A CN111067973A CN201911388232.8A CN201911388232A CN111067973A CN 111067973 A CN111067973 A CN 111067973A CN 201911388232 A CN201911388232 A CN 201911388232A CN 111067973 A CN111067973 A CN 111067973A
- Authority
- CN
- China
- Prior art keywords
- parts
- water
- callicarpa nudiflora
- gel
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a callicarpa nudiflora gel for treating gynecological inflammation, which is prepared from the following raw materials, by weight, 45-55 parts of callicarpa nudiflora extract, β -cyclodextrin 15-25 parts, hypromellose 20-30 parts, water-soluble chitosan 10-20 parts, 0.5-1.5 parts of 0.1% benzalkonium chloride solution, 20-30 parts of propylene glycol, tween-8015-25 parts, and water in an amount of 500 parts to 400 parts.
Description
Technical Field
The invention relates to the field of medicine preparation, and in particular relates to a callicarpa nudiflora gel for treating gynecological inflammation.
Background
Due to the particularity of female reproductive organs, gynecological inflammation becomes a common and frequently-occurring disease of adult females, has various clinical manifestations and complex etiology, is often accompanied by various serious complications, and has great influence on the life and work of the females.
The existing medicines for treating gynecological inflammations such as vaginitis, cervicitis and the like are divided into internal medicines and external medicines. The oral medicine is mainly prepared from Chinese patent medicines, and the preparation forms comprise capsules, pills and the like; the external medicine mainly comprises chemical medicines, most of which contain metronidazole, clotrimazole and other medicines, so that the restriction relationship among vaginal flora is easily destroyed by excessive use, and pathogenic bacteria can generate drug resistance, so that the treatment period is prolonged, and the diseases can not be effectively treated. The external treatment has special significance in clinical gynecology due to the anatomical and physiological characteristics of women. In recent years, in the research on vaginitis, cervicitis and the like, a traditional Chinese medicine external treatment method is adopted, and a better effect is achieved. The vaginal topical drug has the characteristics of high local drug concentration, low preparation dosage, safety, effectiveness and the like, and has higher clinical evaluation. The vagina has abundant capillary vessels and lymphatic vessels, and the vagina has no definite nerve endings, so that the pain stimulation of a patient is small when the medicine is administered, and the medicine is an effective medicine release part for specific diseases such as cervicitis, vaginitis and the like. The medicine can be placed in the vagina and absorbed into local or whole body blood circulation through vaginal mucosa, thus avoiding the first pass effect of liver and the physiological checkpoint effect of gastrointestinal tract, generating better biocompatibility with human body, enhancing adhesiveness, having the functions of slow release and controlled release to the medicine, increasing the effective concentration of the focus part, improving bioavailability and enhancing the curative effect of the medicine, and achieving the aim of local or whole body treatment.
The medicines for vaginal administration in the current market comprise flushing fluid, vaginal effervescent tablets, suppositories, film agents and other dosage forms. The action time of the flushing fluid is short, and the flushing fluid is not easy to penetrate into the deep part of the vagina; the tablet is inconvenient to use, is easy to cause foreign body sensation in the vagina and easily injures the vagina; after the suppository is dissolved, the liquid is easy to flow out of the vagina and pollute clothes, so that the action time is short, and the medicine is difficult to release completely; the vaginal pellicle is prepared by using a polymer film as a carrier and is stuffed into the vagina for use, although the preparation and the use are convenient, the contact surface of the medicine and the mucous membrane is small. The gel is a macromolecular network system which contains two or more than two kinds of gel, consists of solid and liquid phases and has semisolid properties. The gel preparation is prepared by dissolving or uniformly distributing the medicine in the gel, has better adhesiveness and film forming property, can prolong the detention time, is easy to coat, can permeate into mucosal folds, has no foreign body sensation and no irritation, can improve the compliance of patients, is clean and easy to clean, is one of the new drug forms which are most actively shown in the international medical market in recent years, and is also an external drug with the most market potential.
Callicarpa nudiflora is the dry leaf of Callicarpa nudiflora hook.et. arn. of Callicarpa, and has antiinflammatory, toxic substance removing, astringent, and hemostatic effects. The Chinese patent medicine nakedflower beautyberry preparation consisting of the medicinal material extract, such as nakedflower beautyberry tablets, nakedflower beautyberry capsules, nakedflower beautyberry granules, nakedflower beautyberry bacteriostatic gel and the like, has wider clinical application.
Disclosure of Invention
The invention aims to provide a callicarpa nudiflora gel for treating gynecological inflammation, which improves the bioavailability and the action time.
The invention is realized by the following scheme:
a callicarpa nudiflora gel for treating gynecological inflammation is prepared from the following raw materials in parts by weight:
45-55 parts of callicarpa nudiflora extract, 15-25 parts of β -cyclodextrin, 20-30 parts of hydroxypropyl methylcellulose, 10-20 parts of water-soluble chitosan, 0.5-1.5 parts of 0.1% benzalkonium chloride solution, 20-30 parts of propylene glycol, 5-25 parts of tween-8015 and 500 parts of water in balance of 400-.
Further, the callicarpa nudiflora extract is prepared by the following method:
micronizing fresh Callicarpa nudiflora, soaking in 6-8 times of water under negative pressure for 0.5h, recovering normal pressure instantly, heating and extracting for 1.5h, filtering the extractive solution, concentrating the 1/2 filtrate, drying, subjecting the other part of filtrate to macroporous adsorbent resin column chromatography, washing the column with water, discarding the water washing solution, eluting with 10-90% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders.
Further, soaking for 0.5h under the vacuum degree of-0.08 to-0.02 MPa.
Preferably, the feed additive is prepared from the following raw materials in parts by weight:
45 parts of callicarpa nudiflora extract, 15 parts of β -cyclodextrin, 20 parts of hydroxypropyl methylcellulose, 10 parts of water-soluble chitosan, 0.5 part of 0.1% benzalkonium chloride solution, 20 parts of propylene glycol, 20 parts of tween-8015 parts of water, and the balance of water to 400 parts.
Preferably, the feed additive is prepared from the following raw materials in parts by weight:
55 parts of callicarpa nudiflora extract, 25 parts of β -cyclodextrin, 30 parts of hydroxypropyl methylcellulose, 20 parts of water-soluble chitosan, 1.5 parts of 0.1% benzalkonium chloride solution, 30 parts of propylene glycol, 8025 parts of tween-80 and the balance of water to 500 parts.
Preferably, the feed additive is prepared from the following raw materials in parts by weight:
50 parts of callicarpa nudiflora extract, 20 parts of β -cyclodextrin, 25 parts of hydroxypropyl methylcellulose, 15 parts of water-soluble chitosan, 1 part of 0.1% benzalkonium chloride solution, 25 parts of propylene glycol, 8020 parts of tween-80 and water in balance to 450 parts.
Further, the callicarpa nudiflora gel for treating gynecological inflammation is prepared by the following steps:
s1, weighing a proper amount of callicarpa nudiflora extract, β -cyclodextrin, hydroxypropyl methylcellulose, water-soluble chitosan, 0.1% benzalkonium chloride solution, propylene glycol and tween-80 according to the parts by weight;
s2, adding the callicarpa nudiflora extract into a saturated aqueous solution prepared from β -cyclodextrin at 55-65 ℃, stirring for 1.5-2.5 hours, cooling, standing for 5.5-6.5 hours, filtering, washing with a proper amount of distilled water, and drying to obtain a callicarpa nudiflora extract clathrate;
s3, adding a proper amount of water into the weighed hydroxypropyl methylcellulose, heating to 75-85 ℃, stirring, cooling, adding propylene glycol, stirring, adding a small amount of water-soluble chitosan on the surface of the solution in several times, fully stirring, and adding a proper amount of water to fully swell the solution to obtain a clear solution;
s4, adding the weighed benzalkonium chloride solution with the concentration of 0.1% into the clarified solution, and uniformly stirring to obtain a mixed solution;
s5, uniformly stirring the callicarpa nudiflora extract inclusion compound and the weighed Tween-80, adding the obtained mixed solution, uniformly stirring, and adding a proper amount of water to enable the total amount of the medicine to reach 400-500 parts, thus obtaining the gel.
The gel has the advantages of large contact area with the affected part, lasting effect, no irritation, convenient administration, little pollution, quick dissolution, high bioavailability, and safe and effective treatment of vaginitis and cervicitis.
Detailed Description
The present invention will be described in detail with reference to specific examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that variations and modifications can be made by persons skilled in the art without departing from the spirit of the invention. All falling within the scope of the present invention.
In the following examples, the callicarpa nudiflora extract was prepared by the following method: micronizing fresh Callicarpa nudiflora, soaking in 6-8 times of water under negative pressure for 0.5h, recovering normal pressure instantly, heating and extracting for 1.5h, filtering the extractive solution, concentrating the 1/2 filtrate, drying, subjecting the other part of filtrate to macroporous adsorbent resin column chromatography, washing the column with water, discarding the water washing solution, eluting with 10-90% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders.
Example 1
A callicarpa nudiflora gel for treating gynecological inflammation is prepared by the following steps:
s1, weighing 45 parts of callicarpa nudiflora extract, β -cyclodextrin 15 parts, 20 parts of hydroxypropyl methylcellulose, 10 parts of water-soluble chitosan, 0.5 part of 0.1% benzalkonium chloride solution, 20 parts of propylene glycol, 20 parts of tween-8015 parts and water in parts by weight, and complementing the balance to 400 parts;
s2, adding the callicarpa nudiflora extract into a saturated aqueous solution prepared from β -cyclodextrin at 55-65 ℃, stirring for 1.5-2.5 hours, cooling, standing for 5.5-6.5 hours, filtering, washing with a proper amount of distilled water, and drying to obtain a callicarpa nudiflora extract clathrate;
s3, adding a proper amount of water into the weighed hydroxypropyl methylcellulose, heating to 75-85 ℃, stirring, cooling, adding propylene glycol, stirring, adding a small amount of water-soluble chitosan on the surface of the solution in several times, fully stirring, and adding a proper amount of water to fully swell the solution to obtain a clear solution;
s4, adding the weighed benzalkonium chloride solution with the concentration of 0.1% into the clarified solution, and uniformly stirring to obtain a mixed solution;
s5, uniformly stirring the callicarpa nudiflora extract inclusion compound and the weighed Tween-80, adding the obtained mixed solution, uniformly stirring, and adding a proper amount of water to enable the total amount of the medicine to reach 400-500 parts, thus obtaining the gel.
Example 2
A callicarpa nudiflora gel for treating gynecological inflammation is prepared by the following steps:
s1, weighing 55 parts of callicarpa nudiflora extract, 25 parts of β -cyclodextrin, 30 parts of hydroxypropyl methylcellulose, 20 parts of water-soluble chitosan, 1.5 parts of 0.1% benzalkonium chloride solution, 30 parts of propylene glycol, 8025 parts of tween-80 and the balance of water to 500 parts;
s2, adding the callicarpa nudiflora extract into a saturated aqueous solution prepared from β -cyclodextrin at 55-65 ℃, stirring for 1.5-2.5 hours, cooling, standing for 5.5-6.5 hours, filtering, washing with a proper amount of distilled water, and drying to obtain a callicarpa nudiflora extract clathrate;
s3, adding a proper amount of water into the weighed hydroxypropyl methylcellulose, heating to 75-85 ℃, stirring, cooling, adding propylene glycol, stirring, adding a small amount of water-soluble chitosan on the surface of the solution in several times, fully stirring, and adding a proper amount of water to fully swell the solution to obtain a clear solution;
s4, adding the weighed benzalkonium chloride solution with the concentration of 0.1% into the clarified solution, and uniformly stirring to obtain a mixed solution;
s5, uniformly stirring the callicarpa nudiflora extract inclusion compound and the weighed Tween-80, adding the obtained mixed solution, uniformly stirring, and adding a proper amount of water to enable the total amount of the medicine to reach 400-500 parts, thus obtaining the gel.
Example 3
A callicarpa nudiflora gel for treating gynecological inflammation is prepared by the following steps:
s1, weighing 50 parts of callicarpa nudiflora extract, β -cyclodextrin 20 parts, 25 parts of hydroxypropyl methylcellulose, 15 parts of water-soluble chitosan, 1 part of 0.1% benzalkonium chloride solution, 25 parts of propylene glycol, 8020 parts of tween-80 and water in a balance of 450 parts;
s2, adding the callicarpa nudiflora extract into a saturated aqueous solution prepared from β -cyclodextrin at 55-65 ℃, stirring for 1.5-2.5 hours, cooling, standing for 5.5-6.5 hours, filtering, washing with a proper amount of distilled water, and drying to obtain a callicarpa nudiflora extract clathrate;
s3, adding a proper amount of water into the weighed hydroxypropyl methylcellulose, heating to 75-85 ℃, stirring, cooling, adding propylene glycol, stirring, adding a small amount of water-soluble chitosan on the surface of the solution in several times, fully stirring, and adding a proper amount of water to fully swell the solution to obtain a clear solution;
s4, adding the weighed benzalkonium chloride solution with the concentration of 0.1% into the clarified solution, and uniformly stirring to obtain a mixed solution;
s5, uniformly stirring the callicarpa nudiflora extract inclusion compound and the weighed Tween-80, adding the obtained mixed solution, uniformly stirring, and adding a proper amount of water to enable the total amount of the medicine to reach 400-500 parts, thus obtaining the gel.
Application example
50 cases of gynecological inflammation patients are selected, clinically diagnosed as bacterial vaginitis, mycotic vaginitis and cervicitis, aged 20-52 years, have not received gynecological treatment within one month, and women in gestation period and lactation period are excluded. After receiving the callicarpa nudiflora gel of the example 1 for treatment, one treatment course lasts for 8 days, bacterial vaginitis and mycotic vaginitis are 1 treatment course, and cervicitis is 2-3 treatment courses, and the results are as follows: the effective rate of bacterial vaginitis and mycotic vaginitis is 100 percent, and the effective rate of cervicitis is 96.5 percent. During the treatment process, the patients have no obvious adverse reaction.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (7)
1. The callicarpa nudiflora gel for treating gynecological inflammation is characterized by being prepared from the following raw materials in parts by weight:
45-55 parts of callicarpa nudiflora extract, 15-25 parts of β -cyclodextrin, 20-30 parts of hydroxypropyl methylcellulose, 10-20 parts of water-soluble chitosan, 0.5-1.5 parts of 0.1% benzalkonium chloride solution, 20-30 parts of propylene glycol, 5-25 parts of tween-8015 and 500 parts of water in balance of 400-.
2. The callicarpa nudiflora gel for treating gynecological inflammation as claimed in claim 1, wherein said callicarpa nudiflora extract is prepared by the following method:
micronizing fresh Callicarpa nudiflora, soaking in 6-8 times of water under negative pressure for 0.5h, recovering normal pressure instantly, heating and extracting for 1.5h, filtering the extractive solution, concentrating the 1/2 filtrate, drying, subjecting the other part of filtrate to macroporous adsorbent resin column chromatography, washing the column with water, discarding the water washing solution, eluting with 10-90% ethanol, filtering the eluate, concentrating, drying, and mixing the two powders.
3. The callicarpa nudiflora gel for treating gynecological inflammation as claimed in claim 2, wherein the soaking is carried out for 0.5h under a vacuum degree of-0.08 to-0.02 MPa.
4. The callicarpa nudiflora gel for treating gynecological inflammation according to claim 1, wherein the gel is prepared from the following raw materials in parts by weight:
45 parts of callicarpa nudiflora extract, 15 parts of β -cyclodextrin, 20 parts of hydroxypropyl methylcellulose, 10 parts of water-soluble chitosan, 0.5 part of 0.1% benzalkonium chloride solution, 20 parts of propylene glycol, 20 parts of tween-8015 parts of water, and the balance of water to 400 parts.
5. The callicarpa nudiflora gel for treating gynecological inflammation according to claim 1, wherein the gel is prepared from the following raw materials in parts by weight:
55 parts of callicarpa nudiflora extract, 25 parts of β -cyclodextrin, 30 parts of hydroxypropyl methylcellulose, 20 parts of water-soluble chitosan, 1.5 parts of 0.1% benzalkonium chloride solution, 30 parts of propylene glycol, 8025 parts of tween-80 and the balance of water to 500 parts.
6. The callicarpa nudiflora gel for treating gynecological inflammation according to claim 1, wherein the gel is prepared from the following raw materials in parts by weight:
50 parts of callicarpa nudiflora extract, 20 parts of β -cyclodextrin, 25 parts of hydroxypropyl methylcellulose, 15 parts of water-soluble chitosan, 1 part of 0.1% benzalkonium chloride solution, 25 parts of propylene glycol, 8020 parts of tween-80 and water in balance to 450 parts.
7. The callicarpa nudiflora gel for treating gynecological inflammation as claimed in claim 1, wherein it is prepared by the following method:
s1, weighing a proper amount of callicarpa nudiflora extract, β -cyclodextrin, hydroxypropyl methylcellulose, water-soluble chitosan, 0.1% benzalkonium chloride solution, propylene glycol and tween-80 according to the parts by weight;
s2, adding the callicarpa nudiflora extract into a saturated aqueous solution prepared from β -cyclodextrin at 55-65 ℃, stirring for 1.5-2.5 hours, cooling, standing for 5.5-6.5 hours, filtering, washing with a proper amount of distilled water, and drying to obtain a callicarpa nudiflora extract clathrate;
s3, adding a proper amount of water into the weighed hydroxypropyl methylcellulose, heating to 75-85 ℃, stirring, cooling, adding propylene glycol, stirring, adding a small amount of water-soluble chitosan on the surface of the solution in several times, fully stirring, and adding a proper amount of water to fully swell the solution to obtain a clear solution;
s4, adding the weighed benzalkonium chloride solution with the concentration of 0.1% into the clarified solution, and uniformly stirring to obtain a mixed solution;
s5, uniformly stirring the callicarpa nudiflora extract inclusion compound and the weighed Tween-80, adding the obtained mixed solution, uniformly stirring, and adding a proper amount of water to enable the total amount of the medicine to reach 400-500 parts, thus obtaining the gel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911388232.8A CN111067973A (en) | 2019-12-30 | 2019-12-30 | Callicarpa nudiflora gel for treating gynecological inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911388232.8A CN111067973A (en) | 2019-12-30 | 2019-12-30 | Callicarpa nudiflora gel for treating gynecological inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111067973A true CN111067973A (en) | 2020-04-28 |
Family
ID=70319370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911388232.8A Pending CN111067973A (en) | 2019-12-30 | 2019-12-30 | Callicarpa nudiflora gel for treating gynecological inflammation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111067973A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007188A (en) * | 2007-01-26 | 2007-08-01 | 李荣秀 | Drug-releasing vagina obstruction composition and preparation thereof |
| CN105456528A (en) * | 2014-09-04 | 2016-04-06 | 九芝堂股份有限公司 | Suppository for treating gynecological inflammation and preparation method thereof |
| CN107126484A (en) * | 2017-04-26 | 2017-09-05 | 合肥海大生物医药科技有限公司 | It is a kind of to treat callicarpa nudiflora gel of gynaecological imflammation and preparation method thereof |
| CN108524684A (en) * | 2018-06-28 | 2018-09-14 | 黄河科技学院 | Effective fraction with anti-cervicitis effect in callicarpa nudiflora |
-
2019
- 2019-12-30 CN CN201911388232.8A patent/CN111067973A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007188A (en) * | 2007-01-26 | 2007-08-01 | 李荣秀 | Drug-releasing vagina obstruction composition and preparation thereof |
| CN105456528A (en) * | 2014-09-04 | 2016-04-06 | 九芝堂股份有限公司 | Suppository for treating gynecological inflammation and preparation method thereof |
| CN107126484A (en) * | 2017-04-26 | 2017-09-05 | 合肥海大生物医药科技有限公司 | It is a kind of to treat callicarpa nudiflora gel of gynaecological imflammation and preparation method thereof |
| CN108524684A (en) * | 2018-06-28 | 2018-09-14 | 黄河科技学院 | Effective fraction with anti-cervicitis effect in callicarpa nudiflora |
Non-Patent Citations (4)
| Title |
|---|
| 冯年平，等: "《中药及功效性化妆品经皮给药技术》", 31 May 2019, 中国医药科技出版社 * |
| 周晓梅，等: "外用壳聚糖碘络合物联合内服裸花紫珠片抗人乳头瘤病毒感染临床疗效观察", 《中国现代药物应用》 * |
| 环球医药网: "**妇科凝胶/**妇科控销产品/裸花紫珠妇科凝胶", 《HTTPS://WWW.QGYYZS.NET/BUSINESS/ZS537463.HTM》 * |
| 陈端端，等: "保妇康栓和裸花紫珠栓治疗念珠菌性阴道炎的疗效对比观察", 《实用中西医结合临床》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103920072A (en) | Chitosan antibacterial gel and preparation method thereof | |
| EA029649B1 (en) | Pomegranate-peel polyphenol gel used to treat gynecological inflammation diseases and method for preparation thereof | |
| CN107137498B (en) | Traditional Chinese medicine gel for treating haemorrhoids and preparation method thereof | |
| CN108853003A (en) | A kind of Nifuratel-Nysfungin soft-capsule type suppository and preparation method thereof | |
| CN101254270B (en) | External use traditional Chinese medicine preparation for curing gynecology inflammation and method of preparing the same | |
| CN101099730A (en) | Oral solid preparation containing ambroxol hydrochloride and guaifenesin active components | |
| CN105879006A (en) | Pharmaceutical composition for treating diabetic foot ulcer as well as preparation method and application of pharmaceutical composition | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN111067973A (en) | Callicarpa nudiflora gel for treating gynecological inflammation | |
| CN114146051B (en) | Traditional Chinese medicine gel for promoting tissue regeneration and curing ulcer and preparation method thereof | |
| CN108938703A (en) | The gynecological gel of quick antibacterial | |
| CN101766603A (en) | Intramuscular injection solution for enhancing immunity | |
| WO2018161890A1 (en) | Application of berberine in preparing drug for treating acute soft tissue injury | |
| CN104721234A (en) | Periplaneta Americana extract product ion-activated in-situ gel and preparation method thereof | |
| CN1771981A (en) | Pile ointment | |
| CN105326954A (en) | Traditional Chinese medicine composition for treating blepharitis and preparing method thereof | |
| CN111166794A (en) | A Chinese medicinal composition for treating gynecological diseases | |
| CN105853614A (en) | Gynaecological capsule | |
| CN111759905A (en) | Cataplasm for treating osteoarthritis and preparation method thereof | |
| CN100592912C (en) | Externally used compound preparation for treating gynecology disease and method for preparing the same | |
| CN104434992A (en) | Biological adhesive vaginal tablet of periplaneta americana extract and preparation method of biological adhesive vaginal tablet | |
| CN1785264A (en) | Chinese medicinal composition for treating strangury patterns and preparation method of its oral liquid, tablet and capsule | |
| CN115414414B (en) | Traditional Chinese medicine composition and nose washing agent as well as preparation method and application thereof | |
| CN109125703A (en) | A kind of pharmaceutical composition and preparation method thereof for treating vaginitis | |
| CN1076864A (en) | Skin health-care liquid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200428 |
|
| RJ01 | Rejection of invention patent application after publication |